Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SeaStar Medical Holding (ICUCW) Gains from Sales and Divestitures (2023 - 2025)

SeaStar Medical Holding's Gains from Sales and Divestitures history spans 3 years, with the latest figure at $75.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 97.03% year-over-year to $75.0; the TTM value through Dec 2025 reached $75.0, down 97.03%, while the annual FY2025 figure was $75.0, 97.03% down from the prior year.
  • Gains from Sales and Divestitures reached $75.0 in Q4 2025 per ICUCW's latest filing, down from $747.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $205947.0 in Q4 2023 to a low of $75.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 3 years is $54623.9, with a median of $9194.0 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 98.77% in 2024, then surged 44.61% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $205947.0 in 2023, then tumbled by 98.77% to $2529.0 in 2024, then tumbled by 97.03% to $75.0 in 2025.
  • Per Business Quant, the three most recent readings for ICUCW's Gains from Sales and Divestitures are $75.0 (Q4 2025), $747.0 (Q3 2025), and $13295.0 (Q2 2025).